This high prevalence of autoantibody to PARP1 (22.4%) was notable, and meanwhile there was very low frequency of autoantibodies to BRCA1 (4.3%) and to BRCA2 (1.1%) in lung cancer sera. The gene discussed is BRCA2; the disease is lung carcinoma.